ChromaVision develops test for aggressive cancers
This article was originally published in Clinica
Executive Summary
ChromaVision Medical Systems is developing a test for assessing the aggressiveness of cancer based on its Automated Cellular Imaging System. In a collaboration with the University of Southern California, Kenneth Norris Jr Comprehensive Cancer Center, the company plans to develop an objective tumour angiogenesis test that evaluates the density of new blood vessels, which enable tumour growth. The new test could help identify patients who have particularly aggressive cancers and who may benefit from new anti-angiogenesis drugs currently under development, said the San Juan Capistrano, California-based company.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.